0000000000458305

AUTHOR

M Vitale

Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study

Background: Cancer survival is a key measure of the effectiveness of health-care systems. EUROCARE-the largest cooperative study of population-based cancer survival in Europe-has shown persistent differences between countries for cancer survival, although in general, cancer survival is improving. Major changes in cancer diagnosis, treatment, and rehabilitation occurred in the early 2000s. EUROCARE-5 assesses their effect on cancer survival in 29 European countries. Methods: In this retrospective observational study, we analysed data from 107 cancer registries for more than 10 million patients with cancer diagnosed up to 2007 and followed up to 2008. Uniform quality control procedures were a…

research product

Tomografia WAM integrata dell’area sud-tirrenica e siciliana.

research product

Risk assessment of selection for restistant PrP alleles on milk production in Valle del Belice

research product

PRELIMINARY COMPARISON FOR GENES INVOLVED IN BIOFILMS IN COAGULASE-NEGATIVE STAPHYLOCOCCI (CONS) AND S. AUREUS STRAINS ISOLATED FROM MILK SAMPLES OF SICILIAN FARMS

research product

Molecular characterization of biofilm-forming S.aureus field isolates and their treatment

research product

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50–75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2–3 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and…

research product

Regulation of the biosynthesis of the dalbavancin precursor A40926

research product